Position in DSGN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$5,557,000
+$2,667,666 QoQ
Shares Held
384,036
+41.4% QoQ
Ownership
0.614%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
#26
of 136 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 97%
Shared 0%
None 3%
Common Shares in DSGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026KENNEDY CAPITAL MANAGEMENT LLC holds $451,584,893 across 62 Biotechnology names. DSGN ranks #34 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
544,994 | $42,656,680 | |
| 2 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
193,215 | $21,452,661 | |
| 3 | NRIX |
Nurix Therapeutics, Inc.
|
724,508 | $17,576,564 | |
| 4 | CORT |
Corcept Therapeutics Inc
|
201,979 | $17,562,074 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
|
134,019 | $16,428,049 | |
| 6 | MGTX |
MeiraGTx Holdings plc
|
1,105,421 | $14,934,237 | |
| 7 | ADMA |
Adma Biologics, Inc.
|
1,755,152 | $14,690,622 | |
| 8 | NAMS |
NewAmsterdam Pharma Co N.V.
|
421,374 | $14,280,364 |
All Filings in DSGN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,557,000 | 384,036 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $2,889,334 | 271,554 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $469,215 | 50,023 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $221,464 | 29,411 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $50,583 | 15,010 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $55,518 | 14,383 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $88,021 | 14,266 | Shares | Sole | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||